Certolizumab pegol
Certolizumab pegol (pronunciation: ser-toe-LIZ-oo-mab PEG-ol) is a biologic medication used in the treatment of several autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Etymology
The name "Certolizumab pegol" is derived from the components of the drug. "Certolizumab" is the name of the monoclonal antibody that targets tumor necrosis factor alpha (TNFα), a protein that plays a key role in promoting inflammation in autoimmune diseases. "Pegol" refers to the polyethylene glycol (PEG) component of the drug, which extends its half-life in the body.
Pharmacology
Certolizumab pegol works by binding to TNFα, thereby blocking its interaction with its receptors and reducing inflammation. It is administered by subcutaneous injection.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Tumor necrosis factor alpha: A cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction.
- Polyethylene glycol: A polyether compound with many applications from industrial manufacturing to medicine.
- Subcutaneous injection: A method of administering medication under the skin.
See Also
External links
- Medical encyclopedia article on Certolizumab pegol
- Wikipedia's article - Certolizumab pegol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski